The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory

References

• Halsted WS . I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann. Surg.20(5), 497–555 (1894).
   PubMedGoogle Scholar
• Mottet N , BellmuntJ, BollaMet al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol.71(4), 618–629 (2017).
   PubMed Web of Science ®Google Scholar
• Hamdy FC , DonovanJL, LaneJAet al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Eng. J. Med.375(15), 1415–1424 (2016).
   PubMed Web of Science ®Google Scholar
• Kiess AP , BanerjeeSR, MeaseRCet al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q. J. Nucl. Med. Mol. Imaging59(3), 241–268 (2015).
   PubMed Web of Science ®Google Scholar
• Ross JS , SheehanCE, FisherHAet al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Can Res.9(17), 6357–6362 (2003).
   PubMed Web of Science ®Google Scholar
• Taneja SS . ProstaScint® scan: contemporary use in clinical practice. Rev. Urol.6(Suppl 10), S19–S28 (2004).
   PubMedGoogle Scholar
• Afshar-Oromieh A , HetzheimH, KratochwilCet al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J. Nucl. Med.56(11), 1697–1705 (2015).
   PubMed Web of Science ®Google Scholar
• Dietlein M , KobeC, KuhnertGet al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol. Imaging Biol.17(4), 575–584 (2015).
   PubMed Web of Science ®Google Scholar
• Kelly J , Amor-CoarasaA, NikolopoulouAet al. Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging. Eur. J. Nucl. Med. Mol. Imaging44(4), 647–661 (2017).
   PubMed Web of Science ®Google Scholar
• Hovels AM , HeesakkersRA, AdangEM, JagerGJ, StrumS, HoogeveenYL. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin. Radiol.63(4), 387–395 (2008).
   PubMed Web of Science ®Google Scholar
• Maurer T , GschwendJE, RauscherIet al. Diagnostic efficacy of gallium-psma positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J. Urol.195(5), 1436–1443 (2016).
   PubMed Web of Science ®Google Scholar
• van Leeuwen PJ , EmmettL, HoBet al. Prospective evaluation of 68Gallium-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer. BJU Int.119(2), 209–215 (2017).
   PubMed Web of Science ®Google Scholar
• Rauscher I , MaurerT, BeerAJet al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J. Nucl. Med.57(11), 1713–1719 (2016).
   PubMed Web of Science ®Google Scholar
• Bluemel C , KrebsM, PolatBet al. 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-Choline-PET/CT. Clin. Nucl. Med.41(7), 515–521 (2016).
   PubMed Web of Science ®Google Scholar
• Pyka T , OkamotoS, DahlbenderMet al. Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging43(12), 2114–2121 (2016).
   PubMed Web of Science ®Google Scholar
• Froehner M , TomaM, ZophelK, NovotnyV, LaniadoM, WirthMP. PSMA-PET/CT-positive Paget disease in a patient with newly diagnosed prostate cancer: imaging and bone biopsy findings. Case Rep. Urol. 2017, 1654231 (2017).
   PubMedGoogle Scholar
• Rauscher I , MaurerT, FendlerWP, SommerWH, SchwaigerM, EiberM. (68)Ga-PSMA ligand PET/CT in patients with prostate cancer: how we review and report. Cancer Imaging16(1), 14 (2016).
   PubMedGoogle Scholar
• Perera M , PapaN, ChristidisDet al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur. Urol.70(6), 926–937 (2016).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , DreicerR, PaciorekA, CarrollPR, KonetyB. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J. Urol.179(3), 906–910; discussion 910 (2008).
   PubMed Web of Science ®Google Scholar
• Eiber M , MaurerT, SouvatzoglouMet al. Evaluation of hybrid (6)(8)Ga-PSMA Ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med.56(5), 668–674 (2015).
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR , HellmanS. Oligometastases revisited. Nat. Rev. Clin. Oncol.8(6), 378–382 (2011).
   PubMed Web of Science ®Google Scholar
• Clark ME , SmithRR. Liver-directed therapies in metastatic colorectal cancer. J. Gastro. Oncol.5(5), 374–387 (2014).
   PubMedGoogle Scholar
• Singh D , YiWS, BrasacchioRAet al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Intern. J. Radiat. Oncol. Biol. Phys. 58(1), 3–10 (2004).
   PubMed Web of Science ®Google Scholar
• Tosoian JJ , GorinMA, RossAE, PientaKJ, TranPT, SchaefferEM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol.14(1), 15–25 (2017).
   PubMed Web of Science ®Google Scholar
• Suardi N , GandagliaG, GallinaAet al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur. Urol.67(2), 299–309 (2015).
   PubMed Web of Science ®Google Scholar
• Jilg CA , RischkeHC, ReskeSNet al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J. Urol.188(6), 2190–2197 (2012).
   PubMed Web of Science ®Google Scholar
• Decaestecker K , De MeerleerG, LambertBet al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Rad. Oncol.9, 135 (2014).
   PubMed Web of Science ®Google Scholar